N. prodotti: 0
Totale ordine: € 0,00
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
Online ISSN 1827-1839
Lange C. 1, 2, Aasland J. 1, Ødegård A. 3, Hatlinghus S. 3, Winnerkvist A. 4, Mattsson E. 1, 2, Myhre H. O. 1, 2
1 Department of Surgery, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway;
2 Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway;
3 Department of Radiology, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway;
4 Department of Thoracic Surgery, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway
Aim: Aim of the study was to assess if endovascular treatment is a feasible alternative in patients with descending thoracic aortic disease.
Methods: Seventy-three patients were admitted for stent-grafting of descending thoracic aortic disease during the period 1997-2008. The majority of the patients had aneurysm (35) or type B dissection (21), but also traumas, penetrating ulcers and other conditions were treated. Sixteen (22%) were unfit for open surgery. Thirty-four (47%) of the patients were symptomatic and 18 had rupture. The primary technical success rate was 96%.
Results: Early mortality (<30 days) for the whole group was 3%. Early endoleak (<30 days) was identified in 11 patients (15%) of whom 4 (5%) had a secondary procedure. In addition, two trauma patients required insertion of a new stent-graft due to stent-graft collapse. Two patients had stroke, one had paraplegia and two paraparesis. Mean follow-up was 3.1 years (range 0-12 years). Late endoleak (>30 days) was identified in 5 patients (7%) treated by 6 secondary procedures. One patient (1.7%) had an explant. Two patients have had extensions of endografts due to increasing diameter of the aorta at the distal end of the stent-graft.
Conclusion: Endovascular treatment seems to be a viable alternative in patients with descending thoracic aortic disease.